1A and B). The recovery values for the short-term stored samples were lowest for the protein-free cryomedium with 5% DMSO (69.00 ± 6.66%) and highest using BSA (77.40 ± 4.97%). Directly after thawing of the PBMC after short-term storage, the cell viability was high in all samples with values over 96%, independent of the cryomedium. selleck compound Viability decreased marginally in all samples after overnight rest (Fig. 1C) with results between 91.05 ± 1.90% (protein-free medium with 5% DMSO) and 94.75 ± 1.59% (FBS with 10% DMSO). After long-term storage, no significant differences in the recovery and viability could be detected (Fig. 1B and D), compared to the short-term results. The recovery results, normalized to

the short-term performance, show a mean value of 1.00 ± 0.05 directly after thawing and 0.97 ± 0.05 24 h later. Additionally, the viability of all samples, both directly after thawing (1.00 ± 0.00) and after overnight rest (1.01 ± 0.01), was identical to the short-term results. Cryopreservation in all serum-free cryomedia gave high viability and recovery values with maximum results for both the BSA-based medium and the protein-free medium with 10% DMSO. Cells were long-term stable in all of the cryomedia. The maintenance of T-cell responses during cryopreservation is most important. Therefore, PBMC cryopreserved in the five different media were tested in IFN-γ Saracatinib ELISpot using CMV

and CEF peptide pools as immunogenic antigens after up to 4 weeks and after, on the average, 6 months of storage (Table 1). To classify positive responses, the average number of spot forming cells (SFC) per 106 PBMC was determined; three replicates were used for this calculation. Following “Standardization and Validation Issues of ELISpot Assay” (Janetzki et al., 2005) we used the definition of responder R > 4D and R > 55 [R is the reagent SFC/106 PBMC, D corresponding Nintedanib (BIBF 1120) to SFC for diluent (background)]. Using the definition above, after short- and long-term storage 12/13 PBMC samples were responsive to the CMV and 9/13 to the CEF (Table 1) peptide pool,

independent of the cryomedium. Also, with 0 to 12 spot-forming cells per 106 PBMC, the background was very low, independent of cryomedium used and storage duration (data not shown). The results indicated, that after cryopreservation using the HSA-based medium, the specific reactivity mainly against CMV antigens was reduced in several samples (e.g. donors #1 and #5, Table 1), whereas using the protein-free medium with only 5% DMSO, the response against both stimulants was decreased, independent of storage duration (e.g. donors #6 and #12, Table 1). In contrast, the response to antigen stimulation after cryopreservation using BSA-based medium and protein-free medium supplemented with 10% DMSO was comparable to the FBS-based medium. In summary, these two media represent alternatives to serum-containing media.